M&A Deal Summary |
|
---|---|
Date | 2019-06-18 |
Target | Frontline Medical Communications |
Sector | Marketing |
Buyer(s) | WebMD Health |
Deal Type | Add-on Acquisition |
SEARCH BY
Try For Free 7-Day Free Trial
Category | Company |
---|---|
Sector | Digital Media |
Employees | 1,700 |
Revenue | 705M USD (2016) |
WebMD Health Corp. is a provider of health information services, serving consumers, physicians, healthcare professionals, employers, and health plans through our public and private online portals, mobile platforms and health-focused publications. WebMD Health Corp. is based in New York City.
DEAL STATS | # |
---|---|
Overall | 12 of 25 |
Sector (Marketing) | 2 of 2 |
Type (Add-on Acquisition) | 11 of 23 |
State (New Jersey) | 3 of 3 |
Country (United States) | 11 of 20 |
Year (2019) | 1 of 3 |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2018-10-12 |
prIME Oncology
Atlanta, Georgia, United States prIME Oncology, Inc. is a provider of oncology and hematology Independent Medical Education designed to deliver data and insights that help you enhance your decision-making abilities and improve patients’ clinical results. prIME Oncology, Inc. is based in Atlanta, Georgia. |
Buy | - |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2019-08-12 |
QxMD
Vancouver, British Columbia, Canada QxMD is a digital learning technology company that makes it easier for healthcare professionals (HCPs) to discover the latest evidence and decision support tools for use in clinical practice. QxMD HCP engagement platform comprises a library of trusted apps that provide millions of members with fast access to full-text research, continuing medical education (CME), and up-to-date tools that drive disease recognition and therapy optimization. Powered by a sophisticated personalization engine, the platform aggregates PubMed feeds, journal table of contents (TOCs), 450+ diagnostic tools, micro-CME courses and more. QxMD also serves other healthcare constituents such as hospitals, libraries, scholarly publishers, and nearly 50% of the world's top-25 pharmaceutical companies. |
Buy | - |